+1-800-267-5763
Upon successful completion of this continuing education program, participants will be better able to:
- Describe the role of the complement cascade in the pathophysiology of geographic atrophy (GA) and the mechanisms of action for C3 and C5 inhibitors.
- Evaluate the efficacy of pegcetacoplan and avacincaptad pegol in slowing GA lesion growth by interpreting data from their respective phase III clinical trials.
- Compare the safety profiles of pegcetacoplan and avacincaptad pegol, with a focus on common and serious adverse events.
- Discuss emerging and future therapeutic strategies for GA, including gene therapy, cell-based treatments, and neuroprotective agents.
Scientific Planning Committee and Conflicts of Interest Disclosure
| Dr. Bernard Hurley, MD, FRCSC | Chair of Scientific Planning Committee, Author I have a relationship with a for-profit and/or not-for-profit to disclose: Direct financial payments including receipt of honoraria: Allergan, Novartis, Alcon, Bayer, Roche, Biogen Membership on advisory boards or speakers’ bureaus: Teva, Apellis, Biogen, Roche, Bayer, Novartis |
| Dr. Jesia Hasan | Member of Scientific Planning Committee, Author I have a relationship with a for-profit and/or not-for-profit to disclose: Membership on advisory boards or speakers’ bureau: AbbVie, Astellas, Apotex, Apellis, Bayer, Biogen, Roche, Novartis |
| Dr. Amin Kherani, MD, FRCSC | Member of Scientific Planning Committee, Author I have a relationship with a for-profit and/or not-for-profit to disclose: Direct financial payments including receipt of honoraria: AbbVie, Alcon, Bayer, Bausch + Lomb, Novartis, Allergan, Roche and Appellis Funded grants or clinical trials: Bayer, Novartis, Roche/Genentech, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Ophthotech, Regeneron, Regenexbio, Iveris Bio Inc, Ophthea, Alexion All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity: MD Collaborate |
| Dr. Deepa Yoganathan | Member of Scientific Planning Committee, Author I have a relationship with a for-profit and/or not-for-profit to disclose: Direct financial payments including receipt of honoraria: Amgen, Astellas, Bayer, Biogen, Roche, Sentrex Membership on advisory boards or speakers’ bureau: Amgen, Astellas, Bayer, Biogen, Roche Funded grants or clinical trials: Roche, ANI |
Artificial Intelligence (AI) Disclosure
Artificial intelligence (AI) technology was utilized to generate some images contained within this educational module. These images are provided solely for illustrative and educational purposes. They do not depict actual patients or clinical findings and should not be interpreted as a substitute for clinical judgment or real-world diagnostic imaging.
Accreditation
This module is an Accredited Self-Assessment Activity (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Ophthalmological Society (COS). You may claim a maximum of 1.5 HOURS (credits are automatically calculated).
Acknowledgement of Support
This educational activity is supported by independent medical education grants from Apellis and Astellas.